The semaglutide injection brand name you'll see in the UK — and why it matters

You've found a box labelled Wegovy. Here's what that means in practice.

Picture the moment your delivery arrives. A plain, unbranded box lands at your door via DPD tracked delivery, and inside is a Wegovy KwikPen. The name Wegovy is the UK brand Novo Nordisk uses for semaglutide when it is prescribed for weight management. Each pre-filled pen contains enough solution for four once-weekly injections, and the pen is designed to be simple to use without any assembly. The technique for injecting semaglutide is straightforward once shown, but your Patient Information Leaflet walks through every step in detail and that is always the definitive guide.

What the brand name signals beyond the manufacturer is the licensed indication. The MHRA approves medicines for specific purposes, and Wegovy's authorisation covers weight management in adults with a BMI of 30 or above, or 27 or above alongside at least one weight-related condition such as high blood pressure or obstructive sleep apnoea. That licence is distinct from Ozempic's, which was designed around blood-sugar control in people with type 2 diabetes. The ingredient is semaglutide in both cases, but the clinical context is entirely separate. You can read more about the broader Wegovy treatment overview if you want the full picture before speaking to a prescriber.

Ozempic carries the same molecule, so why isn't it prescribed for weight loss?

This is the question our prescribers hear most often when a patient has read about semaglutide online. Ozempic was developed and trialled primarily for glycaemic control, and its UK licence reflects that. The dose range is different too: Ozempic runs up to 1 mg (or 2 mg in some presentations) whereas the Wegovy weight-management pathway starts at 0.25 mg and titrates up to 2.4 mg, with a 7.2 mg single-dose pen now also approved by the MHRA as of April 2026. Prescribing Ozempic off-label for weight loss is not something a responsible prescriber would do routinely, and it is worth knowing that supply of Ozempic has been restricted to protect people with diabetes who depend on it.

Some readers arrive here after seeing references to Ozempic and weight-loss injections in the press. The honest answer is that the journalism was often loose with brand names. The clinical trials that established semaglutide's effectiveness in obesity used the Wegovy formulation and dosing schedule. When you see the STEP 1 trial figures (roughly 15% average body-weight reduction over 68 weeks) that is Wegovy 2.4 mg, not Ozempic. The STEP 1 trial published in the New England Journal of Medicine is the evidence base behind the Wegovy licence.

How the brand name question fits into your wider decision

Knowing the correct brand name is the first step; what follows is working out whether this treatment is clinically appropriate for you. The semaglutide injection pathway at a regulated UK pharmacy starts with a consultation reviewed by a GPhC-registered Independent Prescriber, a real clinician reads your answers, not automated software. Eligibility depends on BMI, any relevant conditions and your medical history as a whole. Lower BMI thresholds can apply for some ethnic backgrounds under UK guidance.

Cost is a practical factor worth thinking through early. Private Wegovy pricing has moved significantly since Eli Lilly's list-price changes in 2025, and the market range for semaglutide has also shifted. A Wegovy price comparison can help set realistic expectations before you commit to any provider. At nume, one transparent price covers the consultation, prescription, treatment and free next-working-day delivery, nothing billed separately, no automatic renewal.

For people who are curious whether something other than an injection might suit them, it is worth noting that a licensed oral semaglutide tablet for weight management now exists in the UK, you can read about the non-injection semaglutide option to understand how it compares. And if you want to understand what happens in your body after the injection is given, the page on when semaglutide peaks after injection covers the pharmacology in plain terms.

When you are ready to talk through whether Wegovy is clinically suitable for you, our prescribers are available. Speak to our prescribers through a free consultation at nume, reviewed the same day, with no obligation and no subscription if treatment goes ahead.